Hemolytic-uremic syndrome historical perspective: Difference between revisions

Jump to navigation Jump to search
Line 34: Line 34:
*The association between [[Shiga toxin|Shiga-toxin]]-producing bacteria and [[Hemolytic-uremic syndrome|HUS]] was made during 35 years ago<ref name=":0" />.
*The association between [[Shiga toxin|Shiga-toxin]]-producing bacteria and [[Hemolytic-uremic syndrome|HUS]] was made during 35 years ago<ref name=":0" />.
*In 1983,  Karmali and colleagueswas the first to discover the association between Escherichia coli and the development of [[HUS]]<ref name=":0" />.
*In 1983,  Karmali and colleagueswas the first to discover the association between Escherichia coli and the development of [[HUS]]<ref name=":0" />.
*In [year], membrane cofactor protein (MCP), complement factor H (CFH) and  factor I (IF) mutations were first implicated in the pathogenesis of non–Shiga toxin–associated HUS<ref>{{Cite journal
*In [year], [[membrane cofactor protein]] (MCP), complement factor H (CFH) and  factor I (IF) mutations were implicated in the pathogenesis of non–Shiga toxin–associated HUS<ref>{{Cite journal
  | author = [[Jessica Caprioli]], [[Marina Noris]], [[Simona Brioschi]], [[Gaia Pianetti]], [[Federica Castelletti]], [[Paola Bettinaglio]], [[Caterina Mele]], [[Elena Bresin]], [[Linda Cassis]], [[Sara Gamba]], [[Francesca Porrati]], [[Sara Bucchioni]], [[Giuseppe Monteferrante]], [[Celia J. Fang]], [[M. K. Liszewski]], [[David Kavanagh]], [[John P. Atkinson]] & [[Giuseppe Remuzzi]]
  | author = [[Jessica Caprioli]], [[Marina Noris]], [[Simona Brioschi]], [[Gaia Pianetti]], [[Federica Castelletti]], [[Paola Bettinaglio]], [[Caterina Mele]], [[Elena Bresin]], [[Linda Cassis]], [[Sara Gamba]], [[Francesca Porrati]], [[Sara Bucchioni]], [[Giuseppe Monteferrante]], [[Celia J. Fang]], [[M. K. Liszewski]], [[David Kavanagh]], [[John P. Atkinson]] & [[Giuseppe Remuzzi]]
  | title = Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
  | title = Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
Line 48: Line 48:


==Outbreaks==
==Outbreaks==
There have been several outbreaks of [disease name], which are summarized below:
There have been several outbreaks of HUS, which are summarized below:
 
Shiga toxin-producing (STEC) Escherichia coli O157


==Landmark Events in the Development of Treatment Strategies==
==Landmark Events in the Development of Treatment Strategies==

Revision as of 15:35, 20 August 2018

Hemolytic-uremic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic-uremic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic-uremic syndrome historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic-uremic syndrome historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic-uremic syndrome historical perspective

CDC on Hemolytic-uremic syndrome historical perspective

Hemolytic-uremic syndrome historical perspective in the news

Blogs on Hemolytic-uremic syndrome historical perspective

Directions to Hospitals Treating Hemolytic-uremic syndrome

Risk calculators and risk factors for Hemolytic-uremic syndrome historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Historical Perspective

Discovery

  • HUS was first described by Gasser and colleagues in paper published in 1955[1][2] .
  • The association between Shiga-toxin-producing bacteria and HUS was made during 35 years ago[2].
  • In 1983, Karmali and colleagueswas the first to discover the association between Escherichia coli and the development of HUS[2].
  • In [year], membrane cofactor protein (MCP), complement factor H (CFH) and factor I (IF) mutations were implicated in the pathogenesis of non–Shiga toxin–associated HUS[3]

Outbreaks

There have been several outbreaks of HUS, which are summarized below:

Shiga toxin-producing (STEC) Escherichia coli O157

Landmark Events in the Development of Treatment Strategies

In [year], [diagnostic test/therapy] was developed by [scientist] to treat/diagnose [disease name].

Impact on Cultural History

Famous Cases

The following are a few famous cases of disease name:

References

  1. A. Schieppati, P. Ruggenenti, R. P. Cornejo, F. Ferrario, G. Gregorini, P. Zucchelli, E. Rossi & G. Remuzzi (1992). "Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome". Journal of the American Society of Nephrology : JASN. 2 (11): 1640–1644. PMID 1610985. Unknown parameter |month= ignored (help)
  2. 2.0 2.1 2.2 Phillip I. Tarr, Carrie A. Gordon & Wayne L. Chandler (2005). "Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome". Lancet (London, England). 365 (9464): 1073–1086. doi:10.1016/S0140-6736(05)71144-2. PMID 15781103. Unknown parameter |month= ignored (help)
  3. Jessica Caprioli, Marina Noris, Simona Brioschi, Gaia Pianetti, Federica Castelletti, Paola Bettinaglio, Caterina Mele, Elena Bresin, Linda Cassis, Sara Gamba, Francesca Porrati, Sara Bucchioni, Giuseppe Monteferrante, Celia J. Fang, M. K. Liszewski, David Kavanagh, John P. Atkinson & Giuseppe Remuzzi (2006). "Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome". Blood. 108 (4): 1267–1279. doi:10.1182/blood-2005-10-007252. PMID 16621965. Unknown parameter |month= ignored (help)

Template:WH Template:WS